Therapeutic Area: Oncology

Biophysicochemical motifs in T cell receptor sequences as a potential biomarker for high-grade serous ovarian carcinoma

Ostmeyer J, et al.
PLOS ONE
June 2021
Authors and Affiliates
Jared Ostmeyer 1, Elena Lucas 2, Scott Christley 1, Jayanthi Lea 3, Nancy Monson 4, Jasmin Tiro 1, Lindsay G Cowell 5; 1 Department of Population and Data Sciences, UT Southwestern Medical Center, Dallas, TX, United States of America. 2 Department of Pathology, UT Southwestern Medical Center, Dallas, TX, United States of America. 3 Department of Obstetrics and Gynecology, UT Southwestern Medical Center, Dallas, TX, United States of America. 4 Department of Neurology and Neurotherapeutics, Department of Immunology, UT Southwestern Medical Center, Dallas, TX, United States of America. 5 Department of Population and Data Sciences, Department of Immunology, UT Southwestern Medical Center, Dallas, TX, United States of America.

T Cell Receptor Repertoires Acquired via Routine Pap Testing May Help Refine Cervical Cancer and Precancer Risk Estimates

Christley S, et al.
Frontiers in Immunology
June 2021
Authors and Affiliates
Scott Christley 1, Jared Ostmeyer 1, Lisa Quirk 1, Wei Zhang 2, Bradley Sirak 3, Anna R Giuliano 3, Song Zhang 1, Nancy Monson 2, Jasmin Tiro 1, Elena Lucas 4,5, Lindsay G Cowell 1,2; 1 Department of Population and Data Sciences, UT Southwestern Medical Center, Dallas, TX, United States. 2 Department of Neurology and Neurotherapeutics, Department of Immunology, UT Southwestern Medical Center, Dallas, TX, United States. 3 Center for Immunization and Infection Research, Moffitt Cancer Center, Tampa, FL, United States. 4 Department of Pathology, UT Southwestern Medical Center, Dallas, TX, United States. 5 Department of Pathology, Parkland Health and Hospital System, Dallas, TX, United States

B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma

Ruffin AT, et al.
Nature Communications
June 2021
immuneAccess
Authors and Affiliates
Ayana T Ruffin 1,2,3,4, Anthony R Cillo 1,2,4, Tracy Tabib 5, Angen Liu 6, Sayali Onkar 1,2,3,4, Sheryl R Kunning 1,2,4, Caleb Lampenfeld 1,2,4, Huda I Atiya 4,7, Irina Abecassis 1,2,4, Cornelius H L Kürten 8, Zengbiao Qi 5, Ryan Soose 6, Umamaheswar Duvvuri 4,5, Seungwon Kim 6, Steffi Oesterrich 4,9,10, Robert Lafyatis 5,6, Lan G Coffman 4,7, Robert L Ferris 1,2,4,6,11, Dario A A Vignali 1,2,4,11, Tullia C Bruno 12,13,14,15; 1 Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA. 2 Tumor Microenvironment Center, Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA. 3 Program in Microbiology and Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 4 Hillman Cancer Center, Pittsburgh, PA, USA. 5 Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. 6 Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA. 7 Division of Hematology and Oncology, Department of Medicine, Hillman Cancer Center, Pittsburgh, PA, USA. 8 Department of Otorhinolaryngology, University Duisburg-Essen, Essen, Germany. 9 Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA. 10 Women's Cancer Research Center, Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, PA, USA. 11 Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. 12 Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA. tbruno@pitt.edu. 13 Tumor Microenvironment Center, Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA. tbruno@pitt.edu. 14 Hillman Cancer Center, Pittsburgh, PA, USA. tbruno@pitt.edu. 15 Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. tbruno@pitt.edu.

Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome

Wang Y, et al.
Blood Cancer Journal
May 2021
Authors and Affiliates
Yucai Wang 1, Sutapa Sinha 1, Linda E Wellik 1, Charla R Secreto 1, Karen L Rech 2, Timothy G Call 1, Sameer A Parikh 1, Saad S Kenderian 1, Eli Muchtar 1, Suzanne R Hayman 1, Amber B Koehler 1, Daniel L Van Dyke 3, Jose F Leis 4, Susan L Slager 5, Haidong Dong 6, Neil E Kay 1, Rong He 7, Wei Ding 8; 1 Division of Hematology, Mayo Clinic, Rochester, MN, USA. 2 Division of Hematopathology, Mayo Clinic, Rochester, MN, USA. 3 Division of Laboratory Genetics and Genomics, Mayo Clinic, Rochester, MN, USA. 4 Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA. 5 Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA. 6 Department of Immunology, Mayo Clinic, Rochester, MN, USA. 7 Division of Hematopathology, Mayo Clinic, Rochester, MN, USA. He.Rong@mayo.edu. 8 Division of Hematology, Mayo Clinic, Rochester, MN, USA. Ding.Wei@mayo.edu.

Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic

Zhang X, et al.
Nature Communications
May 2021
Authors and Affiliates
Xuqing Zhang 1, Mengyao Luo 1, Shamael R Dastagir 1, Mellissa Nixon 1, Annie Khamhoung 1, Andrea Schmidt 1, Albert Lee 1, Naren Subbiah 1, Douglas C McLaughlin 1, Christopher L Moore 1, Mary Gribble 1, Nicholas Bayhi 1, Viral Amin 1, Ryan Pepi 1, Sneha Pawar 1, Timothy J Lyford 1, Vikram Soman 1, Jennifer Mellen 1, Christopher L Carpenter 1, Laurence A Turka 1, Thomas J Wickham 1, Tiffany F Chen 2; 1 Rubius Therapeutics, Inc., Cambridge, MA, USA. 2 Rubius Therapeutics, Inc., Cambridge, MA, USA. tiffany.chen@rubiustx.com.

Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways

Ho WJ, et al.
Genome Biology
May 2021
Authors and Affiliates
Won Jin Ho 1,2,3, Rossin Erbe 1,4, Ludmila Danilova 1, Zaw Phyo 1, Emma Bigelow 1, Genevieve Stein-O'Brien 4, Dwayne L Thomas 2nd 1,5, Soren Charmsaz 1, Nicole Gross 1, Skylar Woolman 1, Kayla Cruz 1, Rebecca M Munday 1,4, Neeha Zaidi 1,3, Todd D Armstrong 1, Marcelo B Sztein 6, Mark Yarchoan 1, Elizabeth D Thompson 1,3,4, Elizabeth M Jaffee 7,8,9, Elana J Fertig 10,11,12,13; 1 Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 550 N Broadway Suite 1101E, Baltimore, MD, 21209, USA. 2 The Johns Hopkins Cancer Convergence Institute, Baltimore, USA. 3 Skip Viragh Center for Pancreatic Cancer, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, 4M07 Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Baltimore, MD, 21287, USA. 4 McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, USA. 5 Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, USA. 6 Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA. 7 Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 550 N Broadway Suite 1101E, Baltimore, MD, 21209, USA. ejaffee@jhmi.edu. 8 The Johns Hopkins Cancer Convergence Institute, Baltimore, USA. ejaffee@jhmi.edu. 9 Skip Viragh Center for Pancreatic Cancer, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, 4M07 Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Baltimore, MD, 21287, USA. ejaffee@jhmi.edu. 10 Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 550 N Broadway Suite 1101E, Baltimore, MD, 21209, USA. ejfertig@jhmi.edu. 11 McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, USA. ejfertig@jhmi.edu. 12 Department of Applied Mathematics and Statistics, Johns Hopkins University Whiting School of Engineering, Baltimore, MD, USA. ejfertig@jhmi.edu. 13 Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, USA. ejfertig@jhmi.edu.

A subset of cytotoxic effector memory T cells enhances CAR T cell efficacy in a model of pancreatic ductal adenocarcinoma

Konduri V, et al.
Science Translational Medicine
May 2021
immuneAccess
Authors and Affiliates
Vanaja Konduri 1, Sujith K Joseph 2,3, Tiara T Byrd 2,3, Zeid Nawas 2,3, Jonathan Vazquez-Perez 1, Colby J Hofferek 1, Matthew M Halpert 1, Dongliang Liu 4, Zhengdong Liang 4, Yunyu Baig 1, Vita S Salsman 2,3, Damilola Oyewole-Said 1, Anna Tsimelzon 5, Briana A Burns 1, Changyi Chen , 6, Jonathan M Levitt 1,5,7, Qizhi Yao 1,4,8,9, Nabil M Ahmed 2,3,8, Meenakshi Hegde 2,3,8, William K Decker 10,2,8; 1 Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA. 2 Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA. 3 Department of Pediatrics, Division of Hematology and Oncology, Baylor College of Medicine, Houston, TX 77030, USA. 4 Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA. 5 Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA. 6 Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA. 7 Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA. 8 Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA. 9 Michael E. DeBakey VA Medical Center, Center for Translational Research on Inflammatory Diseases (CTRID), Houston, TX 77030, USA. 10 Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA. decker@bcm.edu.

A vaccine targeting mutant IDH1 in newly diagnosed glioma

Platten M, et al.
Nature
May 2021
immuneAccess
Authors and Affiliates
Michael Platten 1,2,3, Lukas Bunse 4,5, Antje Wick 6,7, Theresa Bunse 4,5, Lucian Le Cornet 8, Inga Harting 9, Felix Sahm 10,11, Khwab Sanghvi 4, Chin Leng Tan 4, Isabel Poschke 4,12, Edward Green 4, Sune Justesen 13, Geoffrey A Behrens 14, Michael O Breckwoldt 9, Angelika Freitag 8, Lisa-Marie Rother 8, Anita Schmitt 15, Oliver Schnell 16, Jörg Hense 17, Martin Misch 18, Dietmar Krex 19, Stefan Stevanovic 20, Ghazaleh Tabatabai 21, Joachim P Steinbach 22, Martin Bendszus 9, Andreas von Deimling 10,11, Michael Schmitt 15, Wolfgang Wick 6,7,23; 1 DKTK (German Cancer Consortium) Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. m.platten@dkfz.de. 2 Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany. m.platten@dkfz.de. 3 Immune Monitoring Unit, National Center for Tumor Diseases (NCT), Heidelberg, Germany. m.platten@dkfz.de. 4 DKTK (German Cancer Consortium) Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 5 Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany. 6 Neurology Clinic, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany. 7 NCT, Heidelberg, Germany. 8 NCT Trial Center, NCT, Heidelberg, Germany. 9 Department of Neuroradiology, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany. 10 DKTK CCU Neuropathology, DKFZ, Heidelberg, Germany. 11 Department of Neuropathology, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany. 12 Immune Monitoring Unit, National Center for Tumor Diseases (NCT), Heidelberg, Germany. 13 Immunitrack, Copenhagen, Denmark. 14 DKMS Life Science Lab GmbH, Dresden, Germany. 15 Department of Internal Medicine V, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany. 16 Department of Neurosurgery, University of Freiburg, Freiburg, Germany. 17 Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. 18 Department of Neurosurgery, Charité Medical Center, University of Berlin, Berlin, Germany. 19 Department of Neurosurgery, Carl Gustav Carus University Hospital, University of Dresden, Dresden, Germany. 20 Institute of Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany. 21 Department of Neurology, University of Tübingen, Tübingen, Germany. 22 Dr. Senckenberg Institute of Neurooncology, Frankfurt, Germany. 23 DKTK CCU Neurooncology, DKFZ, Heidelberg, Germany.

IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy

Kohli K, et al.
Journal for ImmunoTherapy of Cancer
May 2021
Authors and Affiliates
Karan Kohli 1,2,3, Lu Yao 4, Theodore Scott Nowicki 5, Shihong Zhang 1, Ralph Graeme Black 1, Brett A Schroeder 1,2,6, Erik A Farrar 7, Jianhong Cao 1, Heather Sloan 1, Dawn Stief 1, Lee D Cranmer 1,2, Michael J Wagner 1,2, Douglas S Hawkins 8, Venu G Pillarisetty 3, Antoni Ribas 9, Jean Campbell 1,10, Robert H Pierce 1,10, Edward Y Kim 11, Robin L Jones 12, Stanley R Riddell 1,3,13, Cassian Yee 7, Seth M Pollack 14,3,15; 1 Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA. 2 Division of Oncology, University of Washington, Seattle, WA, USA. 3 Department of Surgery, University of Washington, Seattle, WA, USA. 4 Poseida Therapeutics, San Diego, CA, USA. 5 Division of Pediatric Hematology/Oncology, University of California, Los Angeles, California, USA. 6 Department of Internal Medicine, Virginia Mason Medical Center, Seattle, WA, USA. 7 MD Anderson, Houston, TX, USA. 8 Division of Hematology and Oncology, Seattle Children's Hospital, Seattle, WA, USA. 9 Division Hematology and Oncology, University of California, Los Angeles, UK. 10 Sensei Biotherapeutics, Gaithersburg, Boston, MD, USA. 11 Department of Radiation Oncology, University of Washington, Seattle, WA, USA. 12 Sarcoma, Royal Marsden Hospital and Institute of Cancer Research, London, UK. 13 Lyell Immunopharma, Seattle, WA, USA. 14 Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA Seth.pollack@northwestern.edu. 15 Division of Oncology, Northwestern University, Chicago, IL, USA.